Remains Confident in Company’s Standalone Opportunities – Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data “As the Company’s third-largest shareholder, we are deeply ...

Proposed 38% Premium Ranks Much Lower Than Average Premium of Approximately 89% for Comparable Biopharma Transactions since 2020 Believes Acceleron Has Significant Momentum Given Recent Positive Data ...

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed ...

Following the private placement announced on 8 January 2024 in Company announcement no. 1 / 2024, Avoro Life Sciences Fund LLC now holds nominally 3,438,184 shares in Zealand Pharma A/S, corresponding ...

Avoro Capital’s Behzad Aghazadeh is among the most prominent investors in biotech, delivering consistent returns at his $6 billion hedge fund. Speaking with STAT’s Adam Feuerstein late last year about ...

Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies. Established in 2010 and headquartered in ...

Believes Company Has Strong Momentum and Continuing as Standalone Entity is Superior Path to a Transaction at the Proposed Price, Particularly with Major Value Inflection Point Coming from Phase 3 ...

Hedge funds specializing in life sciences and fledgling biopharma stocks posted varied results in March, when most stock indices fell sharply. Many funds made money, including one that surged by ...

Who is Avoro Capital Advisors LLC Avoro Capital Advisors LLC does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, ...

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed ...